| scholarly article | Q13442814 |
| P50 | author | J. Hans DeVries | Q57911728 |
| P2093 | author name string | F Holleman | |
| S G H A Swinnen | |||
| P2860 | cites work | Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart | Q80119501 |
| Nice insulins, pity about the evidence | Q80625647 | ||
| Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus | Q24245192 | ||
| Glucose clamp technique: a method for quantifying insulin secretion and resistance | Q34191986 | ||
| Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes | Q34613075 | ||
| Measurement of insulin absorption and insulin action | Q35997985 | ||
| Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies | Q36889115 | ||
| Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes | Q42605636 | ||
| Antegrade intravenous catheterization for metabolic studies in man. | Q44293204 | ||
| Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. | Q44606779 | ||
| Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes | Q44909481 | ||
| A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. | Q46458876 | ||
| Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique | Q46701751 | ||
| Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times | Q46892322 | ||
| To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1 | Q46978232 | ||
| Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. | Q55034466 | ||
| Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study | Q57951497 | ||
| Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes | Q57951508 | ||
| Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo | Q73840622 | ||
| Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes | Q79782724 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1790-1795 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back | |
| P478 | volume | 51 |
| Q37742600 | A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes |
| Q26823562 | An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins |
| Q28646059 | Biosimilar Insulins: Basic Considerations |
| Q26992066 | Biosimilar insulins: guidance for data interpretation by clinicians and users |
| Q83358851 | Current literature in diabetes |
| Q38871135 | Euglycaemic glucose clamp: what it can and cannot do, and how to do it. |
| Q35918397 | How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device |
| Q38176677 | Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice |
| Q45946980 | Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes. |
| Q88271057 | Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas |
| Q33658772 | Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus |
| Q37633455 | Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial |
| Q91874147 | Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes |
| Q46199321 | Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. |
Search more.